
Indegene (INDGN) | Financial Analysis & Statements
TL;DR: Financial Overview - Revenue, Profits & Key Metrics
Latest Quarterly: Jun 2025Income Metrics
Revenue
7.6B
Operating Income
1.3B
17.57%
Net Income
1.2B
15.30%
EPS (Diluted)
₹4.82
Balance Sheet Metrics
Total Assets
33.3B
Total Liabilities
7.1B
Shareholders Equity
26.2B
Debt to Equity
0.27
Cash Flow Metrics
Operating Cash Flow
918.7M
Free Cash Flow
1.5B
Revenue & Profitability Trend
Indegene Income Statement From 2021 to 2025
Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
---|---|---|---|---|---|
Revenue | 28.4B | 25.9B | 23.1B | 16.6B | 9.7B |
Cost of Goods Sold | - | - | - | - | - |
Gross Profit | - | - | - | - | - |
Gross Margin % | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
Operating Expenses | |||||
Research & Development | - | - | - | - | - |
Selling, General & Administrative | - | - | 858.1M | 544.6M | 372.4M |
Other Operating Expenses | 4.9B | 4.3B | 4.5B | 2.9B | 1.5B |
Total Operating Expenses | 4.9B | 4.3B | 5.3B | 3.4B | 1.9B |
Operating Income | 4.5B | 4.3B | 3.4B | 2.5B | 2.2B |
Operating Margin % | 16.0% | 16.6% | 14.6% | 15.3% | 22.7% |
Non-Operating Items | |||||
Interest Income | - | - | 103.0M | 8.0M | 8.8M |
Interest Expense | 220.0M | 494.0M | 313.0M | 46.7M | 391.3M |
Other Non-Operating Income | - | - | - | - | - |
Pre-tax Income | 5.4B | 4.6B | 3.6B | 2.3B | 2.3B |
Income Tax | 1.3B | 1.2B | 969.0M | 636.8M | 457.8M |
Effective Tax Rate % | 24.6% | 26.6% | 26.7% | 28.1% | 19.8% |
Net Income | 4.1B | 3.4B | 2.7B | 1.6B | 1.5B |
Net Margin % | 14.3% | 13.0% | 11.5% | 9.8% | 15.5% |
Key Metrics | |||||
EBITDA | 6.4B | 5.8B | 4.5B | 3.1B | 2.6B |
EPS (Basic) | ₹17.15 | ₹14.09 | ₹11.12 | ₹6.89 | ₹6.24 |
EPS (Diluted) | ₹17.02 | ₹14.09 | ₹11.12 | ₹6.89 | ₹6.24 |
Basic Shares Outstanding | 237142857 | 238896201 | 239268909 | 239268909 | 239268909 |
Diluted Shares Outstanding | 237142857 | 238896201 | 239268909 | 239268909 | 239268909 |
Income Statement Trend
Indegene Balance Sheet From 2021 to 2025
Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
---|---|---|---|---|---|
Assets | |||||
Current Assets | |||||
Cash & Equivalents | 2.4B | 1.9B | 735.8M | 5.1B | 1.3B |
Short-term Investments | 14.4B | 8.5B | 6.4B | 1.2B | 1.1M |
Accounts Receivable | 6.3B | 5.6B | 5.2B | 3.9B | 2.5B |
Inventory | - | - | - | - | - |
Other Current Assets | 1.0B | 1.0B | - | - | 25.9M |
Total Current Assets | 25.3B | 17.9B | 14.5B | 11.3B | 4.6B |
Non-Current Assets | |||||
Property, Plant & Equipment | 1.3B | 1.1B | 0 | 0 | 0 |
Goodwill | 9.0B | 8.6B | 8.4B | 987.4M | 685.1M |
Intangible Assets | 1.9B | 2.0B | 1.9B | 169.5M | 104.9M |
Long-term Investments | - | - | - | - | - |
Other Non-Current Assets | 25.0M | 95.0M | - | - | - |
Total Non-Current Assets | 8.0B | 7.5B | 7.6B | 2.2B | 1.4B |
Total Assets | 33.3B | 25.5B | 22.0B | 13.5B | 6.0B |
Liabilities | |||||
Current Liabilities | |||||
Accounts Payable | 934.0M | 1.2B | 732.9M | 742.2M | 501.9M |
Short-term Debt | 292.0M | 910.0M | 230.5M | 218.8M | 202.7M |
Current Portion of Long-term Debt | - | - | - | - | - |
Other Current Liabilities | 2.5B | 1.7B | 24.6M | 11.8M | - |
Total Current Liabilities | 5.6B | 6.1B | 4.9B | 4.4B | 2.0B |
Non-Current Liabilities | |||||
Long-term Debt | 724.0M | 4.0B | 4.8B | 438.8M | 311.2M |
Deferred Tax Liabilities | - | - | - | - | - |
Other Non-Current Liabilities | - | - | - | - | - |
Total Non-Current Liabilities | 1.5B | 5.1B | 6.5B | 1.5B | 635.3M |
Total Liabilities | 7.1B | 11.2B | 11.4B | 5.9B | 2.6B |
Equity | |||||
Common Stock | 479.0M | 444.0M | 443.0M | 3.5M | 3.1M |
Retained Earnings | - | - | 7.4B | 4.7B | 3.0B |
Treasury Stock | - | - | - | - | - |
Other Equity | - | - | - | - | - |
Total Shareholders Equity | 26.2B | 14.3B | 10.6B | 7.6B | 3.3B |
Key Metrics | |||||
Total Debt | 1.0B | 4.9B | 5.0B | 657.5M | 513.9M |
Working Capital | 19.7B | 11.8B | 9.6B | 6.9B | 2.6B |
Balance Sheet Composition
Indegene Cash Flow Statement From 2021 to 2025
Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
---|---|---|---|---|---|
Operating Activities | |||||
Net Income | 5.4B | 4.6B | 3.6B | 2.3B | 2.0B |
Depreciation & Amortization | - | - | - | - | - |
Stock-Based Compensation | 174.0M | 213.0M | 158.0M | 75.4M | 4.9M |
Working Capital Changes | 134.0M | 753.0M | -1.9B | 538.2M | 85.1M |
Operating Cash Flow | 5.2B | 4.8B | 2.0B | 3.4B | 2.0B |
Investing Activities | |||||
Capital Expenditures | -300.0M | -107.0M | -188.0M | -247.1M | -206.2M |
Acquisitions | -1.1B | -1.7B | -3.9B | -164.2M | -44.7M |
Investment Purchases | -70.7B | -17.0B | -5.0B | -3.9B | -580.0K |
Investment Sales | 64.8B | 15.3B | 110.0M | 2.7B | 0 |
Investing Cash Flow | -7.3B | -3.5B | -9.0B | -1.6B | -251.4M |
Financing Activities | |||||
Share Repurchases | - | - | 0 | -10.2M | -15.6M |
Dividends Paid | - | - | - | - | - |
Debt Issuance | - | 0 | 3.9B | 446.0M | 0 |
Debt Repayment | -4.0B | -67.0M | -182.0M | -511.3M | -1.1B |
Financing Cash Flow | 3.3B | -67.0M | 3.8B | 2.6B | -1.1B |
Free Cash Flow | 4.1B | 5.0B | 1.1B | 2.7B | 1.5B |
Net Change in Cash | 1.2B | 1.2B | -3.2B | 4.3B | 604.2M |
Cash Flow Trend
Indegene Key Financial Ratios
Valuation Ratios
P/E Ratio (TTM)
32.05
Forward P/E
25.05
Price to Book
5.32
Price to Sales
4.76
PEG Ratio
1.14
Profitability Ratios
Profit Margin
14.89%
Operating Margin
17.57%
Return on Equity
15.55%
Return on Assets
12.23%
Financial Health
Current Ratio
4.48
Debt to Equity
3.88
Per Share Data
EPS (TTM)
₹18.09
Book Value per Share
₹108.98
Revenue per Share
₹122.26
Peer Financial Comparison
Company | Market Cap | P/E Ratio | P/B Ratio | ROE | Profit Margin | Debt/Equity |
---|---|---|---|---|---|---|
indgn | 139.2B | 32.05 | 5.32 | 15.55% | 14.89% | 3.88 |
Inventurus Knowledge | 258.4B | 47.45 | 14.34 | 27.16% | 19.61% | 47.81 |
Sagility India | 205.7B | 30.59 | 2.44 | 6.47% | 11.31% | 16.82 |
JSW Steel | 622.8M | 1,012.50 | 1.25 | 0.27% | -9.49% | 41.10 |
Sun Pharmaceutical | 4.0T | 37.73 | 5.42 | 15.08% | 19.29% | 3.26 |
Divi's Laboratories | 1.6T | 67.57 | 10.40 | 14.64% | 23.89% | 0.03 |
Financial data is updated regularly. All figures are in the company's reporting currency.